|
Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias
|
|
CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia
|
|
Clinical relevance of soluble HLA class I molecules in Waldenstrom's Macroglobulinemia
|
|
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia
|
|
Effect of plasmapheresis on hyperviscosity-related retinopathy and retinal hemodynamics in patients with Waldenstrom's macroglobulinemia
|
|
Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia
|
|
Increased Incidence of Transformation and Myelodysplasia/Acute Leukemia in Patients With Waldenström Macroglobulinemia Treated With Nucleoside Analogs
|
|
Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom's macroglobulinemia
|
|
Long term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia
|
|
Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia
|
|
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia
|
|
Targeting NF-kappaB in Waldenstrom macroglobulinemia
|
|
Thalidomide and rituximab in Waldenstrom's macroglobulinemia
|
|
The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia
|
|
Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia
|
